DelveInsight's "XPOVIO Market Size, Forecast, and Market Insight Report" highlights the details around XPOVIO, a ...

Stock analysts at StockNews.com initiated coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever 0.0% of Sorrento Therapeutics shares are owned by institutional investors.

Ko­jin Ther­a­peu­tics, a start­up at­tempt­ing to de­vel­op new treat­ments us­ing pro­grammed cell death, left last month’s JP Mor­gan Health­care Con­fer­ence in a bind.

Crispr Therapeutics AG reported significant revenue declines in Q4 and FY24 due to reduced collaboration revenues, but maintains strong financial health with $298m cash and $1.6bn in marketable ...